Compare STE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STE | BIIB |
|---|---|---|
| Founded | 1985 | 1978 |
| Country | United States | United States |
| Employees | 3700 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3B | 27.1B |
| IPO Year | 2018 | 1996 |
| Metric | STE | BIIB |
|---|---|---|
| Price | $214.72 | $183.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 27 |
| Target Price | ★ $275.20 | $194.72 |
| AVG Volume (30 Days) | ★ 846.3K | 827.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.19% | N/A |
| EPS Growth | ★ 62.73 | N/A |
| EPS | 5.69 | ★ 8.79 |
| Revenue | $5,459,515,000.00 | ★ $9,890,600,000.00 |
| Revenue This Year | $9.88 | N/A |
| Revenue Next Year | $6.32 | N/A |
| P/E Ratio | $37.42 | ★ $21.03 |
| Revenue Growth | ★ 6.24 | 2.22 |
| 52 Week Low | $204.90 | $110.04 |
| 52 Week High | $269.44 | $202.41 |
| Indicator | STE | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 24.65 | 46.95 |
| Support Level | N/A | $181.24 |
| Resistance Level | $254.67 | $186.17 |
| Average True Range (ATR) | 5.90 | 5.30 |
| MACD | -3.20 | -1.14 |
| Stochastic Oscillator | 11.00 | 16.93 |
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).